more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$64.49 USD

-0.20 (-0.31%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $64.61 +0.12 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

Top 19% (47 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Research for AZN

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
BioPharmaceuticals: R&I: Symbicor...		2,362	2,538	2,728	2,721	2,495
BioPharmaceuticals: R&I: Pulmicor...		713	645	962	996	1,466
BioPharmaceuticals: CVRM: Brilint...		1,324	1,358	1,472	1,593	1,581
BioPharmaceuticals: CVRM: Farxiga...		5,963	4,381	3,000	1,959	1,543
BioPharmaceuticals: R&I: Breztri:...		677	398	203	28	2
BioPharmaceuticals: CVRM: Lokelma...		412	289	175	76	14
Rare Disease: Koselugo: World [$M...		331	208	108	38	--
Oncology: World [$M]		17,145	14,631	13,048	10,850	8,667
BioPharmaceuticals: CVRM: World [...		10,585	9,188	8,020	7,096	--
BioPharmaceuticals: R&I: World [$...		6,107	5,765	6,034	5,357	--
BioPharmaceuticals: CVRM: roxadus...		--	0	174	30	--
BioPharmaceuticals: V&I: FluMist:...		216	175	253	--	--
Oncology: Others: World [$M]		224	44	50	--	--
BioPharmaceuticals: CVRM: Others:...		296	366	196	--	--
BioPharmaceuticals: R&I: Others: ...		324	421	594	--	--
Oncology: Enhertu: World [$M]		261	79	17	--	--
Oncology: Tagrisso: Emerging Mark...		1,621	1,567	--	--	--
Oncology: Imfinzi: Emerging Marke...		360	287	--	--	--
Oncology: Lynparza: Emerging Mark...		542	488	--	--	--
Oncology: Calquence: Emerging Mar...		98	45	--	--	--
Oncology: Enhertu: Emerging Marke...		169	51	--	--	--
Oncology: Orpathys: Emerging Mark...		44	33	--	--	--
Oncology: Zoladex: Emerging Marke...		687	657	--	--	--
Oncology: Others: Emerging Market...		165	27	--	--	--
Oncology: Emerging Markets Total ...		3,828	3,537	--	--	--
BioPharmaceuticals: CVRM: Farxiga...		2,211	1,665	--	--	--
BioPharmaceuticals: CVRM: Brilint...		285	286	--	--	--
BioPharmaceuticals: CVRM: Lokelma...		50	20	--	--	--
BioPharmaceuticals: CVRM: roxadus...		271	197	--	--	--
BioPharmaceuticals: CVRM: Crestor...		862	794	--	--	--
BioPharmaceuticals: CVRM: Seloken...		621	839	--	--	--
BioPharmaceuticals: CVRM: Others:...		152	194	--	--	--
BioPharmaceuticals: CVRM: Emergin...		4,586	4,119	--	--	--
BioPharmaceuticals: R&I: Symbicor...	--	753	608	--	--	--
BioPharmaceuticals: R&I: Fasenra:...	--	64	43	--	--	--
BioPharmaceuticals: R&I: Breztri:...	--	161	92	--	--	--
BioPharmaceuticals: R&I: Pulmicor...	--	575	462	--	--	--
BioPharmaceuticals: R&I: Others: ...	--	206	230	--	--	--
BioPharmaceuticals: R&I: Emerging...	--	1,771	1,443	--	--	--
BioPharmaceuticals: V&I: Synagis:...	--	195	173	--	--	--
BioPharmaceuticals: V&I: Emerging...	--	212	1,316	--	--	--
Rare Disease: Soliris: Emerging M...		424	301	--	--	--
Rare Disease: Ultomiris: Emerging...	--	71	38	--	--	--
Rare Disease: Strensiq: Emerging ...		40	35	--	--	--
Rare Disease: Koselugo: Emerging ...		59	26	--	--	--
Rare Disease: Kanuma: Emerging Ma...		29	31	--	--	--
Rare Disease: Emerging Markets [$...		623	431	--	--	--
Other Medicines: Nexium: Emerging...		578	568	--	--	--
Other Medicines: Others: Emerging...		153	220	--	--	--
Other Medicines: Emerging Markets...		731	788	--	--	--
Oncology: Tagrisso: Established R...		782	847	--	--	--
Oncology: Imfinzi: Established Ro...		802	401	--	--	--
Oncology: Lynparza: Established R...		281	269	--	--	--
Oncology: Calquence: Established ...		108	69	--	--	--
Oncology: Zoladex: Established Ro...		118	122	--	--	--
Oncology: Others: Established RoW...		47	10	--	--	--
Oncology: Established RoW [$M]		2,266	1,884	--	--	--
BioPharmaceuticals: CVRM: Andexxa...		45	32	--	--	--
BioPharmaceuticals: CVRM: Establi...		744	684	--	--	--
BioPharmaceuticals: R&I: Symbicor...	--	334	375	--	--	--
BioPharmaceuticals: R&I: Fasenra:...	--	142	142	--	--	--
BioPharmaceuticals: R&I: Breztri:...	--	52	34	--	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	10	3	--	--	--
BioPharmaceuticals: R&I: Pulmicor...	--	42	49	--	--	--
BioPharmaceuticals: R&I: Others: ...	--	6	6	--	--	--
BioPharmaceuticals: R&I: Establis...	--	625	613	--	--	--
Oncology: Orpathys: World [$M]		44	33	--	--	--
BioPharmaceuticals: CVRM: Andexxa...		182	150	--	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	280	116	--	--	--
BioPharmaceuticals: V&I: World [$...	--	1,012	4,736	--	--	--
BioPharmaceuticals: V&I: Establis...	--	295	1,225	--	--	--
BioPharmaceuticals: V&I: Synagis:...	--	177	191	--	--	--
Rare Disease: Soliris: World [$M]		3,145	3,762	--	--	--
Rare Disease: Soliris: Establishe...		317	476	--	--	--
Rare Disease: Ultomiris: Establis...	--	476	310	--	--	--
Rare Disease: Ultomiris: World [$...	--	2,965	1,965	--	--	--
Product Sales: Rare Disease: Stre...		1,152	958	--	--	--
Rare Disease: Strensiq: Establish...		86	76	--	--	--
Rare Disease: Koselugo: Establish...		24	0	--	--	--
Rare Disease: Kanuma: Established...		8	8	--	--	--
Rare Disease: Kanuma: World [$M]		171	160	--	--	--
Product Sales: Rare Disease: Worl...	--	7,764	7,053	--	--	--
Rare Disease: Established RoW [$M...		911	870	--	--	--
Other Medicines: Nexium: Establis...		199	551	--	--	--
Other Medicines: Others: Establis...		8	19	--	--	--
Other Medicines: Others: World [$...		231	340	--	--	--
Other Medicines: Established RoW ...		207	570	--	--	--
Other Medicines: World [$M]		1,176	1,625	--	--	--
Total Product Sales: Emerging Mar...	--	11,751	11,634	--	--	--
Collaboration Revenue: Total [$M]	--	594	1,353	--	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	2	--	--	--	--
Oncology: Tagrisso: World [$M]		5,799	5,444	5,015	4,328	3,189
Oncology: Imfinzi: World [$M]		4,237	2,784	2,412	2,042	1,469
Oncology: Lynparza: World [$M]		2,811	2,638	2,348	1,776	1,198
Oncology: Calquence: World [$M]		2,514	2,057	1,238	522	164
Oncology: Zoladex: World [$M]		952	927	948	888	813
Other medicines: Nexium: World [$...		945	1,285	1,326	1,492	1,483
BioPharmaceuticals: V&I: Synagis:...		546	578	410	372	358
BioPharmaceuticals: R&I: Fasenra:...		1,553	1,396	1,258	949	704
BioPharmaceuticals: CVRM: Crestor...		1,107	1,048	1,096	1,180	1,278
BioPharmaceuticals: CVRM: Seloken...		640	862	951	821	760
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
BioPharmaceuticals: R&I: Symbicor...		726	973	1,065	1,022	829
BioPharmaceuticals: R&I: Pulmicor...		28	65	72	71	110
BioPharmaceuticals: CVRM: Crestor...		55	65	80	92	104
BioPharmaceuticals: CVRM: Seloken...		1	0	1	13	37
Oncology: Zoladex: U.S. [$M]		14	15	13	5	7
Oncology: Tagrisso: U.S. [$M]		2,276	2,007	1,780	1,566	1,268
Other Medicines: Nexium: U.S. [$M...		115	120	128	169	218
BioPharmaceuticals: R&I: Fasenra:...		992	906	790	603	482
BioPharmaceuticals: CVRM: Brilint...		744	744	735	732	710
Oncology: Lynparza: U.S. [$M]		1,254	1,226	1,087	876	626
Oncology: Imfinzi: U.S. [$M]		2,317	1,552	1,245	1,185	1,041
Oncology: Calquence: U.S. [$M]		1,815	1,657	1,089	511	162
BioPharmaceuticals: CVRM: Farxiga...		1,451	1,071	732	569	537
BioPharmaceuticals: CVRM: Lokelma...		214	170	115	57	13
Rare Disease: Koselugo: U.S. [$M]		195	162	104	38	--
Oncology: U.S. [$M]		7,719	6,484	5,359	4,250	3,449
BioPharmaceuticals: CVRM: U.S. [$...		2,752	2,479	2,124	2,083	--
BioPharmaceuticals: R&I: U.S. [$M...		2,547	2,655	2,404	1,941	--
Total Product Sales: Total World ...		43,789	42,998	36,541	25,890	23,565
Total Product Sales: U.S. Sales [...		17,961	17,254	12,000	8,638	7,747
BioPharmaceuticals: V&I: FluMist:...	--	23	21	27	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	260	111	--	--	--
BioPharmaceuticals: CVRM: Farxiga...		1,881	1,297	--	--	--
BioPharmaceuticals: CVRM: Brilint...		271	282	--	--	--
BioPharmaceuticals: CVRM: Lokelma...		58	30	--	--	--
BioPharmaceuticals: CVRM: Andexxa...		62	41	--	--	--
BioPharmaceuticals: CVRM: Crestor...		52	41	--	--	--
BioPharmaceuticals: CVRM: Seloken...		11	14	--	--	--
BioPharmaceuticals: CVRM: Others:...		109	128	--	--	--
BioPharmaceuticals: CVRM: Europe ...		2,503	1,906	--	--	--
BioPharmaceuticals: R&I: Symbicor...	--	549	582	--	--	--
BioPharmaceuticals: R&I: Fasenra:...	--	355	305	--	--	--
BioPharmaceuticals: R&I: Breztri:...	--	81	33	--	--	--
BioPharmaceuticals: R&I: Pulmicor...	--	68	69	--	--	--
BioPharmaceuticals: R&I: Others: ...	--	30	42	--	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	8	2	--	--	--
BioPharmaceuticals: R&I: Europe [...	--	1,164	1,054	--	--	--
BioPharmaceuticals: V&I: Europe [...	--	396	1,027	--	--	--
BioPharmaceuticals: V&I: Synagis:...	--	175	213	--	--	--
BioPharmaceuticals: V&I: FluMist:...	--	188	151	--	--	--
Rare Disease: Soliris: Europe [$M...		670	805	--	--	--
Other Medicines: Nexium: Europe [...		53	46	--	--	--
Other Medicines: Others: Europe [...		52	77	--	--	--
Rare Disease: Europe [$M]		1,529	1,428	--	--	--
Other Medicines: Europe [$M]		105	123	--	--	--
BioPharmaceuticals: CVRM: Farxiga...		420	348	--	--	--
BioPharmaceuticals: CVRM: Brilint...		24	46	--	--	--
BioPharmaceuticals: CVRM: Lokelma...		90	69	--	--	--
BioPharmaceuticals: CVRM: Crestor...		138	148	--	--	--
BioPharmaceuticals: CVRM: Seloken...		7	9	--	--	--
BioPharmaceuticals: CVRM: Others:...		5	10	--	--	--
BioPharmaceuticals: CVRM: Andexxa...		75	77	--	--	--
BioPharmaceuticals: CVRM: Others:...		30	34	--	--	--
BioPharmaceuticals: R&I: Other: U...	--	82	143	--	--	--
BioPharmaceuticals: R&I: Breztri:...	--	383	239	--	--	--
Rare Disease: Soliris: U.S. [$M]		1,734	2,180	--	--	--
Rare Disease: Ultomiris: U.S. [$M...	--	1,750	1,136	--	--	--
Rare Disease: Strensiq: U.S. [$M]	--	937	769	--	--	--
Rare Disease: Kanuma: U.S. [$M]		85	77	--	--	--
Rare Disease: U.S. [$M]	--	4,701	4,324	--	--	--
Other Medicines: Others: U.S. [$M...		18	24	--	--	--
Other Medicines: U.S. [$M]		133	144	--	--	--
Rare Disease: Ultomiris: Europe [...	--	668	481	--	--	--
Rare Disease: Strensiq: Europe [$...		89	78	--	--	--
Rare Disease: Koselugo: Europe [$...		53	20	--	--	--
Rare Disease: Kanuma: Europe [$M]	--	49	44	--	--	--
Total Product Sales: Europe [$M]	--	9,029	8,264	--	--	--
Total Product Sales: Established ...	--	5,048	5,846	--	--	--
BioPharmaceuticals: V&I: FluMist:...	--	4	2	--	--	--
BioPharmaceuticals: V&I: U.S. [$M...	--	109	1,168	--	--	--
Oncology: Tagrisso: Europe [$M]		1,120	1,023	--	--	--
Oncology: Imfinzi: Europe [$M]		758	544	--	--	--
Oncology: Lynparza: Europe [$M]		734	655	--	--	--
Oncology: Calquence: Europe [$M]		493	286	--	--	--
Oncology: Enhertu: Europe [$M]		60	21	--	--	--
Oncology: Enhertu: Established Ro...		32	7	--	--	--
Oncology: Zoladex: Europe [$M]		133	133	--	--	--
Oncology: Europe [$M]		3,332	2,726	--	--	--
Oncology: Others: Europe [$M]		6	6	--	--	--

Revenue - Line of Business Segments	Qtr Estimate	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023
BioPharmaceuticals: R&I: Symbicor...		722	769	520	555	600
BioPharmaceuticals: R&I: Pulmicor...		155	224	219	148	124
BioPharmaceuticals: CVRM: Brilint...		342	323	329	331	331
BioPharmaceuticals: CVRM: Farxiga...		1,940	1,845	1,606	1,554	1,505
BioPharmaceuticals: R&I: Breztri:...		235	219	199	171	163
BioPharmaceuticals: CVRM: Lokelma...		136	114	112	102	100
Rare Disease: Koselugo: World [$M...		114	132	85	87	80
Oncology: World [$M]		4,976	4,760	4,453	4,389	4,382
BioPharmaceuticals: CVRM: World [...		3,153	3,012	2,698	2,683	2,675
BioPharmaceuticals: R&I: World [$...		1,797	1,804	1,590	1,451	1,483
BioPharmaceuticals: CVRM: roxadus...		88	75	--	--	--
BioPharmaceuticals: V&I: FluMist:...		2	7	138	75	0
Oncology: Others: World [$M]		109	107	50	54	54
BioPharmaceuticals: CVRM: Others:...		130	141	58	66	69
BioPharmaceuticals: R&I: Others: ...		79	98	80	67	71
Oncology: Enhertu: World [$M]		127	122	83	73	67
Oncology: Tagrisso: Emerging Mark...		432	488	360	409	408
Oncology: Imfinzi: Emerging Marke...		117	129	90	87	102
Oncology: Lynparza: Emerging Mark...		153	167	133	131	142
Oncology: Calquence: Emerging Mar...		36	39	29	28	24
Oncology: Enhertu: Emerging Marke...		77	83	48	48	48
Oncology: Orpathys: Emerging Mark...		12	12	11	12	13
Oncology: Zoladex: Emerging Marke...		201	214	167	182	171
Oncology: Others: Emerging Market...		66	66	38	42	36
Oncology: Emerging Markets Total ...		1,098	1,202	904	971	987
BioPharmaceuticals: CVRM: Farxiga...		763	711	559	579	576
BioPharmaceuticals: CVRM: Brilint...		78	88	61	64	79
BioPharmaceuticals: CVRM: Lokelma...		21	21	13	13	13
BioPharmaceuticals: CVRM: roxadus...		88	75	63	74	73
BioPharmaceuticals: CVRM: Crestor...		234	241	184	219	217
BioPharmaceuticals: CVRM: Seloken...		146	161	139	149	159
BioPharmaceuticals: CVRM: Others:...		53	67	28	29	34
BioPharmaceuticals: CVRM: Emergin...		1,384	1,365	1,078	1,161	1,182
BioPharmaceuticals: R&I: Symbicor...		197	253	153	195	177
BioPharmaceuticals: R&I: Fasenra:...		19	22	16	19	14
BioPharmaceuticals: R&I: Breztri:...		61	70	38	42	43
BioPharmaceuticals: R&I: Pulmicor...		126	191	183	119	90
BioPharmaceuticals: R&I: Others: ...		37	49	62	45	32
BioPharmaceuticals: R&I: Emerging...		444	588	456	422	360
BioPharmaceuticals: V&I: Synagis:...		41	90	37	32	49
BioPharmaceuticals: V&I: Emerging...		41	90	31	32	46
Rare Disease: Soliris: Emerging M...		129	125	86	124	99
Rare Disease: Ultomiris: Emerging...		35	32	24	17	17
Rare Disease: Strensiq: Emerging ...		10	21	11	5	9
Rare Disease: Koselugo: Emerging ...		24	59	10	11	14
Rare Disease: Kanuma: Emerging Ma...		5	14	5	6	11
Rare Disease: Emerging Markets [$...		203	251	136	163	150
Other Medicines: Nexium: Emerging...		146	172	120	153	149
Other Medicines: Others: Emerging...		33	34	31	37	36
Other Medicines: Emerging Markets...		179	206	151	190	185
Oncology: Tagrisso: Established R...		191	182	163	198	218
Oncology: Imfinzi: Established Ro...		183	170	225	221	222
Oncology: Lynparza: Established R...		66	59	65	71	77
Oncology: Calquence: Established ...		33	32	28	30	27
Oncology: Zoladex: Established Ro...		25	24	50	21	24
Oncology: Others: Established RoW...		30	30	10	10	15
Oncology: Established RoW [$M]		561	521	579	583	614
BioPharmaceuticals: CVRM: Andexxa...		14	8	17	5	14
BioPharmaceuticals: CVRM: Establi...		191	183	161	175	221
BioPharmaceuticals: R&I: Symbicor...		83	75	88	81	86
BioPharmaceuticals: R&I: Fasenra:...		37	33	36	35	36
BioPharmaceuticals: R&I: Breztri:...		19	14	15	12	15
BioPharmaceuticals: R&I: Saphnelo...		4	3	3	3	2
BioPharmaceuticals: R&I: Pulmicor...		9	8	12	11	11
BioPharmaceuticals: R&I: Others: ...		2	2	2	1	2
BioPharmaceuticals: R&I: Establis...		173	149	170	154	160
Oncology: Orpathys: World [$M]		12	12	11	12	13
BioPharmaceuticals: CVRM: Andexxa...		59	47	53	40	45
BioPharmaceuticals: R&I: Saphnelo...		112	91	89	76	68
BioPharmaceuticals: V&I: World [$...		112	212	345	224	88
BioPharmaceuticals: V&I: Establis...		36	21	60	55	27
BioPharmaceuticals: V&I: Synagis:...		35	21	60	51	28
Rare Disease: Soliris: World [$M]		700	739	715	781	814
Rare Disease: Soliris: Establishe...		55	61	68	74	86
Rare Disease: Ultomiris: Establis...		152	143	138	131	110
Rare Disease: Ultomiris: World [$...	--	946	859	825	777	713
Product Sales: Rare Disease: Stre...		340	313	305	285	300
Rare Disease: Strensiq: Establish...		23	22	22	21	22
Rare Disease: Koselugo: Establish...		9	9	9	7	6
Rare Disease: Kanuma: Established...		2	2	2	2	2
Rare Disease: Kanuma: World [$M]		47	53	41	44	46
Product Sales: Rare Disease: Worl...		2,147	2,096	1,971	1,974	1,953
Rare Disease: Established RoW [$M...		241	237	239	235	226
Other Medicines: Nexium: Establis...		35	33	46	51	55
Other Medicines: Others: Establis...		1	1	2	1	3
Other Medicines: Others: World [$...		48	53	57	53	53
Other Medicines: Established RoW ...		36	34	48	52	58
Other Medicines: World [$M]		267	293	266	297	301
Total Product Sales: Emerging Mar...	--	3,349	3,702	2,756	2,939	2,910
Collaboration Revenue: Total [$M]		4	45	277	97	193
Oncology: Imjudo: World [$M]	--	74	62	--	--	--
Oncology: Imjudo: Emerging Market...	--	4	4	--	--	--
Oncology: Imjudo: Established RoW...	--	13	11	--	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	1	1	1	--	1
Alliance Revenue: Total [$M]		482	457	424	377	341
Oncology: Tagrisso: World [$M]		1,608	1,595	1,419	1,465	1,491
Oncology: Imfinzi: World [$M]		1,147	1,113	1,135	1,126	1,076
Oncology: Lynparza: World [$M]		744	705	741	702	717
Oncology: Calquence: World [$M]		790	718	675	654	653
Oncology: Zoladex: World [$M]		273	276	254	239	233
Other medicines: Nexium: World [$...		219	240	209	244	248
BioPharmaceuticals: V&I: Synagis:...		81	171	164	99	87
BioPharmaceuticals: R&I: Fasenra:...		423	358	420	389	406
BioPharmaceuticals: CVRM: Crestor...		292	297	247	275	280
BioPharmaceuticals: CVRM: Seloken...		150	165	144	153	164
Revenue - Geographic Segments	Qtr Estimate	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023
BioPharmaceuticals: R&I: Symbicor...		299	299	137	156	200
BioPharmaceuticals: R&I: Pulmicor...		3	5	5	5	7
BioPharmaceuticals: CVRM: Crestor...		12	10	15	14	12
BioPharmaceuticals: CVRM: Seloken...		0	0	0	--	1
Oncology: Zoladex: U.S. [$M]		5	3	2	5	4
Oncology: Tagrisso: U.S. [$M]		658	623	597	577	581
Other Medicines: Nexium: U.S. [$M...		25	22	26	29	30
BioPharmaceuticals: R&I: Fasenra:...		268	210	275	249	267
BioPharmaceuticals: CVRM: Brilint...		191	163	194	193	178
Oncology: Lynparza: U.S. [$M]		319	288	352	322	311
Oncology: Imfinzi: U.S. [$M]		620	582	609	610	576
Oncology: Calquence: U.S. [$M]		554	494	478	468	485
BioPharmaceuticals: CVRM: Farxiga...		394	473	451	366	339
BioPharmaceuticals: CVRM: Lokelma...		64	52	58	51	49
Rare Disease: Koselugo: U.S. [$M]		55	46	51	54	48
Oncology: U.S. [$M]		2,302	2,084	2,067	1,986	1,962
BioPharmaceuticals: CVRM: U.S. [$...		735	748	780	690	661
BioPharmaceuticals: R&I: U.S. [$M...		830	737	647	609	674
Total Product Sales: Total World ...		12,452	12,177	11,323	11,018	10,882
Total Product Sales: U.S. Sales [...		5,234	4,827	4,814	4,515	4,525
BioPharmaceuticals: V&I: FluMist:...		2	2	7	15	0
BioPharmaceuticals: R&I: Saphnelo...		101	83	82	71	64
BioPharmaceuticals: CVRM: Farxiga...		680	553	525	506	456
BioPharmaceuticals: CVRM: Brilint...		69	67	68	68	68
BioPharmaceuticals: CVRM: Lokelma...		23	18	17	16	14
BioPharmaceuticals: CVRM: Andexxa...		22	18	18	15	15
BioPharmaceuticals: CVRM: Crestor...		10	12	11	9	16
BioPharmaceuticals: CVRM: Seloken...		3	3	3	2	2
BioPharmaceuticals: CVRM: Others:...		36	45	22	27	25
BioPharmaceuticals: CVRM: Europe ...		843	716	679	657	611
BioPharmaceuticals: R&I: Symbicor...		143	142	142	123	137
BioPharmaceuticals: R&I: Fasenra:...		99	93	93	86	89
BioPharmaceuticals: R&I: Breztri:...		35	30	26	19	21
BioPharmaceuticals: R&I: Pulmicor...		17	20	19	13	16
BioPharmaceuticals: R&I: Others: ...		15	14	7	7	7
BioPharmaceuticals: R&I: Saphnelo...		6	4	3	2	1
BioPharmaceuticals: R&I: Europe [...		350	330	317	266	289
BioPharmaceuticals: V&I: Europe [...		7	74	195	122	15
BioPharmaceuticals: V&I: Synagis:...		6	61	67	16	10
BioPharmaceuticals: V&I: FluMist:...	--	0	5	130	56	0
Rare Disease: Soliris: Europe [$M...		118	142	140	163	184
Other Medicines: Nexium: Europe [...		13	13	17	11	14
Other Medicines: Others: Europe [...		11	16	21	8	12
Rare Disease: Europe [$M]		392	401	364	397	381
Other Medicines: Europe [$M]		24	29	38	19	26
BioPharmaceuticals: CVRM: Farxiga...		103	108	71	103	134
BioPharmaceuticals: CVRM: Brilint...		4	5	6	6	6
BioPharmaceuticals: CVRM: Lokelma...		28	23	24	22	24
BioPharmaceuticals: CVRM: Crestor...		36	34	37	33	35
BioPharmaceuticals: CVRM: Seloken...		1	1	2	2	2
BioPharmaceuticals: CVRM: Others:...		5	4	1	1	1
BioPharmaceuticals: CVRM: Andexxa...		22	20	18	20	16
BioPharmaceuticals: CVRM: Others:...		36	25	7	9	9
BioPharmaceuticals: R&I: Other: U...		25	28	9	14	30
BioPharmaceuticals: R&I: Breztri:...		120	105	120	98	84
Rare Disease: Soliris: U.S. [$M]		398	411	421	420	445
Rare Disease: Ultomiris: U.S. [$M...	--	550	482	490	445	434
Rare Disease: Strensiq: U.S. [$M]		283	246	247	237	248
Rare Disease: Kanuma: U.S. [$M]		25	22	23	23	21
Rare Disease: U.S. [$M]		1,311	1,207	1,232	1,179	1,196
Other Medicines: Others: U.S. [$M...		3	2	3	7	2
Other Medicines: U.S. [$M]		28	24	29	36	32
Rare Disease: Ultomiris: Europe [...		209	202	173	184	152
Rare Disease: Strensiq: Europe [$...		24	24	25	22	21
Rare Disease: Koselugo: Europe [$...		26	18	15	15	12
Rare Disease: Kanuma: Europe [$M]		15	15	11	13	12
Total Product Sales: Europe [$M]	--	2,631	2,503	2,496	2,310	2,141
Total Product Sales: Established ...	--	1,238	1,145	1,257	1,254	1,306
BioPharmaceuticals: V&I: FluMist:...	--	0	0	0	4	0
BioPharmaceuticals: V&I: U.S. [$M...	--	25	27	59	15	0
Oncology: Imjudo: U.S. [$M]	--	49	39	--	--	--
Oncology: Imjudo: Europe [$M]	--	8	8	--	--	--
Oncology: Tagrisso: Europe [$M]		327	302	299	281	284
Oncology: Imfinzi: Europe [$M]		227	232	211	208	176
Oncology: Lynparza: Europe [$M]		206	191	191	178	187
Oncology: Calquence: Europe [$M]		167	153	140	128	117
Oncology: Enhertu: Europe [$M]		31	26	20	16	14
Oncology: Enhertu: Established Ro...		19	13	15	9	5
Oncology: Zoladex: Europe [$M]		42	35	35	31	34
Oncology: Europe [$M]		1,015	953	903	849	819
Oncology: Others: Europe [$M]		7	6	1	1	1

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators